Table A1.
Psychometric results from Study 2 (acetazolamide dosage)
| Test | Drug | Time 0 h | Time 2 h | Time 4.5 h | Time 6.5 h |
|---|---|---|---|---|---|
| CFF (hz) | Placebo | 31.4 (0.8) | 32.1 (0.7) | 31.1 (0.6) | 30.9 (0.6) |
| Acetazolamide 250 mg | 31.3 (1.1) | 31.5 (0.8) | 30.0 (0.7) | 31.7 (0.8) | |
| Acetazolamide 1000 mg | 32.2 (0.7) | 31.1 (0.5) | 32.5 (0.5) | 32.2 (0.5) | |
| Pegs correctly placed in 2 min | Placebo | 32.1 (1.5) | 33.5 (1.4) | 32.9 (0.9) | 30.8 (1.2) |
| Acetazolamide 250 mg | 33.1 (1.3) | 33.8 (1.2) | 35.1 (1.4) | 36.0 (1.4) | |
| Acetazolamide 1000 mg | 33.2 (1.0) | 32.9 (0.8) | 31.9 (0.9) | 33.8 (1.0) | |
| VAS wide awake | Placebo | 74.8 (5.4) | 81.1 (3.7) | 75.2 (6.3) | 69.0 (7.3) |
| Acetazolamide 250 mg | 77.2 (4.4) | 70.1 (4.9) | 59.6 (7.0) | 53.9 (8.1) | |
| Acetazolamide 1000 mg*** | 77.4 (5.2) | 51.6 (6.3) | 34.2 (5.3) | 41.3 (5.7) | |
| VAS decline in clear headedness | Placebo | 15.0 (4.3) | 11.3 (3.4) | 9.7 (4.1) | 16.6 (5.6) |
| Acetazolamide 250 mg | 21.5 (5.5) | 22.6 (4.0) | 30.5 (7.5) | 37.4 (7.7) | |
| Acetazolamide 1000 mg*** | 19.3 (5.6) | 45.4 (6.8) | 62.4 (4.1) | 58.4 (8.5) | |
| VAS dizzy | Placebo | 95.5 (1.8) | 95.5 (1.4) | 96.5 (1.1) | 85.8 (4.9) |
| Acetazolamide 250 mg | 95.5 (1.7) | 92.1 (2.3) | 73.1 (7.2) | 70.0 (8.0) | |
| Acetazolamide 1000 mg** | 96.4 (1.7) | 67.9 (7.4) | 48.6 (5.3) | 47.3 (8.3) | |
| VAS hungry | Placebo | 42.1 (5.1) | 55.4 (6.5) | 9.5 (1.7) | 39.4 (2.5) |
| Acetazolamide 250 mg | 37.8 (6.9) | 52.1 (6.6) | 12.1 (4.2) | 23.4 (4.6) | |
| Acetazolamide 1000 mg | 45.1 (7.1) | 66.9 (4.7) | 26.0 (7.1) | 44.7 (5.1) |
*P < 0.05, **P < 0.01, ***P < 0.001 (relative to placebo at and beyond 2 h). Values are mean ± SEM.